Wenzel C, Schmidinger M, Huber H
Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Wien, Osterreich.
Wien Klin Wochenschr. 2001 Apr 30;113(9):306-20.
Breast cancer is the most frequent type of cancer in women. The therapeutic approaches to breast cancer have developed rapidly over the past 20 years, due to the increasing knowledge about the biology of breast cancer. Therefore it was possible to increase response rates as well as the duration of response and survival in neoadjuvant, adjuvant, and palliative treatment. This paper gives a review of the current breast cancer trials. Effective new cytotoxic chemotherapy and hormonal therapy agents, as well as the identification of specific molecular abnormalities (HER2/neu) led to the development of targeted therapeutic interventions in the neoadjuvant, adjuvant, and palliative treatment of breast cancer. Increased understanding of the biology of breast cancer led to the development of rational therapeutic interventions, which are currently under active clinical development.
乳腺癌是女性中最常见的癌症类型。在过去20年中,由于对乳腺癌生物学的认识不断增加,乳腺癌的治疗方法迅速发展。因此,在新辅助治疗、辅助治疗和姑息治疗中,提高缓解率以及缓解持续时间和生存率成为可能。本文对当前的乳腺癌试验进行综述。有效的新型细胞毒性化疗和激素治疗药物,以及特定分子异常(HER2/neu)的识别,促成了乳腺癌新辅助治疗、辅助治疗和姑息治疗中靶向治疗干预措施的发展。对乳腺癌生物学认识的增加导致了合理治疗干预措施的发展,这些措施目前正处于积极的临床开发中。